Celldex Therapeutics, Inc. is a biopharmaceutical company. Co. is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. We show 65 historical shares outstanding datapoints in our CLDX shares outstanding history coverage, used to compute CLDX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CLDX market cap history over the course of time is important for investors
interested in comparing CLDX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CLDX versus a peer is one thing; comparing
CLDX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CLDX can fluctuate over the course of history.
With this page we aim to empower investors researching CLDX by allowing them to research the CLDX market cap history. |
Free CLDX Email Alerts:
Video: The Importance of Market Cap
